What are the key mechanistic, therapeutic, and diagnostic dimensions of TREM2 in Alzheimer's disease progression?

Based on the provided literature, TREM2 is a microglial surface receptor governing the disease-associated microglia (DAM) program. The TREM2 R47H loss-of-function variant increases Alzheimer's risk ~3-fold. Key mechanistic axes: (1) TREM2-APOE lipid sensing axis for debris clearance, (2) TREM2-SYK-PI3K signaling for microglial survival and metabolic fitness, (3) TREM2-dependent phagocytosis of amyloid-beta and tau seeds. Therapeutic strategies include TREM2 agonism, APOE4-TREM2 co-targeting, and stage-specific biomarker-guided switching.

The INVOKE-2 trial (AL002, TREM2 agonist) failed to meet primary endpoints in 2024. This raises questions about mechanism appropriateness, off-target effects from systemic activation, and whether amyloid clearance alone justifies benefit at late stages. TREM2 has dual roles — pro-inflammatory via SYK and potentially protective via metabolic reprogramming — making timing and context critical.

TREM2 biology is highly stage-dependent. In early AD, TREM2 activation promotes amyloid clearance via DAM. In late AD, DAM may become senescent and contribute to chronic inflammation. Biomarker guidance (CSF sTREM2, CHIT1/CHI3L1) could enable patient stratification. The most promising near-term approach is APOE4-TREM2 co-targeting since APOE4 is upstream of TREM2 dysfunction.

TREM2 Showcase Synthesis

Core verdict: TREM2 is a legitimate but timing-sensitive AD target requiring biomarker-guided, stage-specific therapeutic modulation.

Mechanistic consensus: TREM2→TYROBP→SYK→PI3K/AKT drives microglial metabolic fitness and phagocytosis. APOE is a TREM2 ligand; APOE4 reduces TREM2 binding ~50%.

Therapeutic verdict: TREM2 agonism is scientifically justified but INVOKE-2 failure suggests the field needs better patient selection and earlier intervention. APOE4-TREM2 co-targeting is the most promising combination strategy.

Top hypotheses: 1. TREM2-mediated microglial dysfunction (0.812), 2. TREM2 agonism to redirect APOE4 microglia (0.887), 3. CSF sTREM2 biomarker (0.801).